Summary
The Maharashtra Food and Drug Administration has revoked Cipla's drug license for its Pune unit due to violations in packaging and storage practices, specifically concerning Reactin Plus Tablets. Issues included improper storage on the floor, inadequate handling of expired products, and failure to comply with recall protocols for misbranded drugs.